Advertisement

Timing for Narcotic Drugs in Terminal Illness

  • S. Mercadante
Conference paper
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)

Abstract

Pain is a major symptom in cancer. About 30% of patients undergoing oncological treatment and 70% of patients with advanced disease suffer pain due to different causes, such as tumor progression or treatment-related syndromes.

Keywords

Neuropathic Pain Cancer Pain Opioid Analgesic Terminal Illness Opioid Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cleeland CS, Gonin R, Hatfield AK et al (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330: 592–596PubMedCrossRefGoogle Scholar
  2. 2.
    Hanks GW, De Conno F, Ripamonti C et al (1996) Morphine in cancer pain: modes of administration. BMJ 312: 823–826Google Scholar
  3. 3.
    Portenoy RK, Miransky J, Thaler H et al (1992) Pain in ambulatory patients with lung or colon cancer. Cancer 70: 1616–1624PubMedCrossRefGoogle Scholar
  4. 4.
    Mercadante S (1999) Treatment and outcome of cancer pain in advanced cancer patients followed at home. Cancer 85: 1849–1858PubMedCrossRefGoogle Scholar
  5. 5.
    Collin E, Cesselin F (1991) Neurobiological mechanisms of opioid tolerance and dependence. Clin Pharmacol 14: 465–488Google Scholar
  6. 6.
    Portenoy RK (1995) Tolerance to opioid analgesics: clinical aspects. Cancer Surveys 21: 49–65Google Scholar
  7. 7.
    Bruera E, MacMillan D, Hanson J, MacDonald RN (1989) The Edmonton staging system for cancer pain: preliminary report. Pain 37: 203–210PubMedCrossRefGoogle Scholar
  8. 8.
    Mao J, Price D, Mayer DJ (1985) Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61: 353–364CrossRefGoogle Scholar
  9. 9.
    Collins JJ, Berde CB, Grier HE et al (1995) Massive opioid resistance in an infant with a localized metastasis to the midbrain periaqueductal gray. Pain 1995: 271–275CrossRefGoogle Scholar
  10. 10.
    Collin E, Poulain P, Gauvain-Piquard A et al (1993) Is disease progression the major factor in morphine “tolerance” in cancer pain treatment? Pain 55: 319–326PubMedCrossRefGoogle Scholar
  11. 11.
    Portenoy RK, Foley KM (1986) Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 25: 171–186PubMedCrossRefGoogle Scholar
  12. 12.
    Coyle N, Weaver S, Breibart W, Portenoy RK (1994) Delirium as a contributing factor to crescendo pain: three case reports, J Pain Symptom Manage 9: 44–47PubMedCrossRefGoogle Scholar
  13. 13.
    Galer BS, Coyle N, Pasternak GW, Portenoy RK (1992) Individual variability in the response to different opioids: report of five cases. Pain 49: 87–91PubMedCrossRefGoogle Scholar
  14. 14.
    Borgbjerg FM, Nielsen K, Franks I (1996) Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain 64: 123–128PubMedCrossRefGoogle Scholar
  15. 15.
    Mercadante S, Portenoy RK (2000) Opioid poorly responsive cancer pain. Part 1. Clinical considerations. J Pain Symptom Manage, in pressGoogle Scholar
  16. 16.
    Walsh TD (1984) Opiates and respiratory function in advanced cancer. Recent Results. Cancer Res 89: 115–117Google Scholar
  17. 17.
    Mercadante S (1999) Opioid rotation in cancer pain: rationale and clinical aspects. Cancer 86: 1856–1866PubMedCrossRefGoogle Scholar
  18. 18.
    Mercadante S (1999) The role of morphine metabolites in cancer pain. Palliat Med 13: 95–104PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2001

Authors and Affiliations

  • S. Mercadante

There are no affiliations available

Personalised recommendations